March 5, 2018
AGA’s new guideline on medical management of opioid-induced constipation is open until March 30.
The AGA Institute is seeking public comments on a new guideline for the medical management of opioid-induced constipation (OIC). It does not address the role of psychological therapy, alternative medicine approaches, surgery or devices. The guideline and technical review also do not directly address questions regarding the diagnostic evaluation of OIC. Additionally, combination opioid agonists/antagonists are not specifically addressed by the technical review or guideline recommendation statements, though these agents may result in less constipation than pure opioid agonists when used for management of chronic pain.
Review and submit feedback by March 30.
The AGA Institute is seeking public comments on the technical review, clinical practice guideline, Clinical Decision Support Tool and accompanying tables for the medical management of OIC. The technical review is an objective report of the clinical evidence underlying the recommendations for clinical practice presented in the guideline. Please review the following documents:
About the public comment period
This AGA evidence-based clinical practice guideline employs the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system, which provides a user-friendly way to rate the quality of the evidence, as well as the strength of clinical recommendations.
The public comment period is an integral part of AGA’s guideline development process. Public comment allows AGA members, as well as key stakeholders, to review and comment on upcoming guidelines and their accompanying technical reviews.
Once an AGA guideline panel releases the drafts for public comment, identified stakeholders are alerted and have 30 days to submit their comments through an online survey. After the 30-day period ends, the guideline panel reviews and responds to the comments within two weeks. Revisions to the draft documents are at the discretion of the panel, but all comments must be considered and responses internally documented.
More on Constipation
FDA Announces GREAT 5 Public Workshop
Feb. 16, 2018
The three-day public workshop will focus on alcoholic hepatitis and liver disease, and pediatric IBS and functional constipation.
Attend the AGA Postgraduate Course for Practical, Take Home Information
Feb. 12, 2018
Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.
It’s Time to Talk About the Hard Stuff
Feb. 6, 2018
Discussing constipation with patients may be uncomfortable, but providing information on how to relieve symptoms makes the talk worth it.